<DOC>
	<DOCNO>NCT02491398</DOCNO>
	<brief_summary>This study intend Chronic Lymphocytic Leukemia patient already undergo first second treatment drug name bendamustine rituximab . It observe result treatment evaluate efficacy side effect .</brief_summary>
	<brief_title>Efficacy Safety Bendamustine Plus Rituximab Chronic Lympocytic Leukemia</brief_title>
	<detailed_description>This cohort study recruit chronic lymphocytic leukemia ( CLL ) patient treat first second-line Bendamustine plus Rituximab ( BR ) January 2008 December 2014 European centre adhere GIMEMA group ERIC group , aim observe progression-free survival CLL patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Diagnosis CLL / Small Lymphocytic Lymphoma ( CLL/ ) accord World Health Organisation ( WHO ) classification 2008 . Patients treat first secondline Bendamustine plus Rituximab ( BR ) January 2008 December 2014 European centre adhere GIMEMA group ERIC group . Previously untreated CLL patient require therapy accord NCI criterion ( Hallek M et al , Blood 2008 Appendix G ) treat least one cycle BR firstline treatment . CLL patient receive one previous line treatment use alkylating agent and/or purine analogue without monoclonal antibody , require secondline therapy accord NCI criterion ( Hallek M et al , Blood 2008 Appendix G ) treat least one cycle bendamustine rituximab . Age â‰¥ 18 year old . Signed write informed consent accord ICH/EU/GCP national local law . Patients receive 2 line prior therapy . Patients : Transformation CLL aggressive lymphoma ( Richter 's Syndrome ) . HIV infection . Active uncontrolled HCV and/or HBV infection liver cirrhosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>